Graduate School News - Archive

Graduate School News

Showing 6 to 10 of 133.
Pages: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next

Faculty Guest Lecture: Clinical Trials in Adult ALL in the UK and associated correlative scientific studies

Speaker: Professor Adele Fielding, Professor of Haematology, University College London Cancer Institute

Speaker: Professor Adele Fielding, Professor of Haematology, University College London Cancer Institute

Herschel Building

23 March 2016, 10.15 a.m. 


Faculty Guest Lecture: Cancer Prone Syndromes

Speaker: Professor Christian Kratz, Klinik fur Padiatrische Hamatologie und Onkologie Medizinische Hochschule Hannover Germany

Speaker: Professor Christian Kratz, Klinik fur Padiatrische Hamatologie und Onkologie Medizinische Hochschule Hannover Germany

Herschel Building

22 March 2016, 17.00 


ICaMB Seminar: Sweeter but not better: glucose and pulmonary infection

Speaker: Professor Debbie Baines, St Georges, University of London

Speaker: Professor Debbie Baines, St Georges, University of London

Dental Lecture Theatre E

13.00, 9 March 2016 


ICM PI Seminar: Improving Cardiovascular Outcomes in High Risk Patients with Coronary Artery Disease

Speaker: Dr Vijay Kunadian, Senior Lecturer, Honorary Consultant Interventional Cardiologist

Speaker: Dr Vijay Kunadian, Senior Lecturer, Honorary Consultant Interventional Cardiologist

Date and Time: 14 March 2016, 13.00

Venue: Baddiley Clark Seminar Room 


NICR Lecture: Targetting the tumour stroma: New ways for old roads

Speaker: Professor Kairbaan Hodivala-Dilke, Professor of Angiogenesis/Deputy Institute Director Barts Cancer Institute Queen Mary University of London

 

Synopsis: Increasing chemotherapy delivery to tumors, whilst enhancing drug uptake and reducing side effects, is a primary goal of cancer research. In mouse and human cancer models in vivo, we show that co-administration of low dose Cilengitide and Verapamil, increases tumor angiogenesis, leakiness, blood flow and Gemcitabine delivery. This approach reduces tumor growth, metastasis and minimizes side effects whilst extending survival. At a molecular level, this strategy alters gemcitabine transporter and metabolizing enzyme expression levels, enhancing the potency of Gemcitabine within tumor cells in vivo and in vitro. Thus, the dual a ction of low dose Cilengitide, in vessels and tumor cells, improves chemotherapy efficacy. Overall, our data demonstrate that vascular promotion therapy is a novel means to improve cancer treatment.

 

Date: 7 March 2016

Time: 13.00

Venue:  Common Room, Paul O'Gorman Building


rss iconwrite news icon